Shindo Motohiro, Ikuta Katsuya, Addo Lynda, Ito Satoshi, Fujiya Mikihiro, Torimoto Yoshihiro, Kohgo Yutaka
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Case Rep Hematol. 2012;2012:908196. doi: 10.1155/2012/908196. Epub 2012 Sep 12.
Disseminated intravascular coagulation (DIC) frequently occurs in patients with acute promyelocytic leukemia (APL). With the induction of therapy in APL using all-trans retinoic acid (ATRA), DIC can be controlled in most cases as ATRA usually shows immediate improvement of the APL. However, arsenic trioxide (ATO) which has been used for the treatment of relapse in APL patients has shown to take time to suppress APL cells, therefore the control of DIC in APL with ATO treatment is a major problem. Recently, the recombinant soluble thrombomodulin fragment has received a lot of attention as the novel drug for the treatment of DIC with high efficacy. Here, we present a relapsed patient with APL in whom DIC was successfully and safely controlled by rTM during treatment with ATO.
弥散性血管内凝血(DIC)常发生于急性早幼粒细胞白血病(APL)患者中。在使用全反式维甲酸(ATRA)诱导治疗APL时,多数情况下DIC可得到控制,因为ATRA通常能使APL迅速改善。然而,用于治疗APL患者复发的三氧化二砷(ATO)已显示出抑制APL细胞需要时间,因此用ATO治疗APL时控制DIC是一个主要问题。最近,重组可溶性血栓调节蛋白片段作为治疗DIC的高效新药受到了广泛关注。在此,我们报告一例复发的APL患者,在使用ATO治疗期间,rTM成功且安全地控制了DIC。